CancerNetwork Members: Login | Register

Cancer Network
    PUBLICATIONS NEWS PODCASTS TOPICS BLOGS PATIENTS NURSES JOBS CONFERENCES CME SUPPLEMENTS

TOPIC CENTERS

Bone Metastases Breast Cancer Cancer and Genetics Chronic Myeloid Leukemia Colorectal Cancer Complications End-of-Life Transition Gastrointestinal Stromal Tumor Gynecologic Cancers Head & Neck Cancer Health Care Reform Integrative Oncology Kidney Cancer Leukemia and Lymphoma Lung Cancer Melanoma and Other Skin Cancers Multiple Myeloma Nausea & Vomiting Palliative and Supportive Care Pancreatic Cancer Practice Management Prostate Cancer Renal Cell Carcinoma Survivorship Testicular Cancer Triple-Negative Breast Cancer Hematologic Malignancies

MORE INFO

Cancer Management E-Learning E-Textbooks Oncology NEWS Today Blog Contact Us Newsletter Signup Media Kit Subscribe to RSS Success and Balance


Home » Cancer Management Handbook, 11th Edition » Chapter 2: Principles of Radiation Therapy

Cancer Management: A Multidisciplinary Approach, 11th Edition (2008).
Pages: 1  2  3  4  5  
Next
Chapter 2 

Principles of Radiation Therapy

By Kevin A. Camphausen, MD, and Lawrence R. Coia, MD | April 9, 2009

This chapter provides a brief overview of the principles of radiation therapy. The topics to be discussed include the physical aspects of how radiation works (ionization, radiation interactions) and how it is delivered (treatment machines, treatment planning, and brachytherapy). Recent relevant techniques of radiation oncology, such as conformal and stereotactic radiation therapy, also will be presented. These topics are not covered in great tech­nical detail. It is hoped that a basic understanding of radiation treatment will benefit those practicing in other disciplines of cancer management. This chapter does not address the principles of radiobiology, which guide radiation oncologists in determining issues of treatment time, dose, and fractionation or in combining radiation with sensitizers, protectors, and chemotherapy or hormones.

How radiation works


IONIZING RADIATION

Ionizing radiation is energy sufficiently strong to remove an orbital electron from an atom. This radiation can have an electromagnetic form, such as a high-energy photon, or a particulate form, such as an electron, proton, neutron, or alpha particle.

High-energy photons By far, the most common form of radiation used in practice today is the high-energy photon. Photons that are released from the nucleus of a radioactive atom are known as gamma rays. When photons are created electronically, such as in a clinical linear accelerator, they are known as x-rays. Thus, the only difference between the two terms is the origin of the photon.

Inverse square law The intensity of an x-ray beam is governed by the inverse square law. This law states that the radiation intensity from a point source is inversely proportional to the square of the distance away from the radiation source. In other words, the dose at 2 cm will be one-fourth of the dose at 1 cm.

Electron volt Photon absorption in human tissue is determined by the energy of the radiation, as well as the atomic structure of the tissue in question. The basic unit of energy used in radiation oncology is the electron volt (eV); 103 eV = 1 keV, 106 eV = 1 MeV.

PHOTON-TISSUE INTERACTIONS

Three interactions describe photon absorption in tissue: the photoelectric effect, Compton effect, and pair production.

Photoelectric effect In this process, an incoming photon undergoes a collision with a tightly bound electron. The photon transfers practically all of its energy to the electron and ceases to exist. The electron departs with most of the energy from the photon and begins to ionize surrounding molecules. This interaction depends on the energy of the incoming photon, as well as the atomic number of the tissue; the lower the energy and the higher the atomic number, the more likely that a photoelectric effect will take place.

An example of this interaction in practice can be seen on a diagnostic x-ray film. Since the atomic number of bone is 60% higher than that of soft tissue, bone is seen with much more contrast and detail than is soft tissue. The energy range in which the photoelectric effect predominates in tissue is about 10–25 keV.

Compton effect The Compton effect is the most important photon-tissue interaction for the treatment of cancer. In this case, a photon collides with a “free electron,” ie, one that is not tightly bound to the atom. Unlike the photoelectric effect, in the Compton interaction both the photon and electron are scattered. The photon can then continue to undergo additional interac­tions, albeit with a lower energy. The electron begins to ionize with the energy given to it by the photon.

The probability of a Compton interaction is inversely proportional to the energy of the incoming photon and is independent of the atomic number of the material. When one takes an image of tissue using photons in the energy range in which the Compton effect dominates (~25 keV–25 MeV), bone and soft-tissue interfaces are barely distinguishable. This is a result of the atomic number independence.

The Compton effect is the most common interaction occurring clinically, as most radiation treatments are performed at energy levels of about 6–20 MeV. Port films are films taken with such high-energy photons on the treat­ment machine and are used to check the precision and accuracy of the beam; because they do not distinguish tissue densities well, however, they are not equal to diagnostic films in terms of resolution.

Pair production In this process, a photon interacts with the nucleus of an atom, not an orbital electron. The photon gives up its energy to the nucleus and, in the process, creates a pair of positively and negatively charged electrons. The positive electron (positron) ionizes until it combines with a free electron. This generates two photons that scatter in opposite directions.

The probability of pair production is proportional to the logarithm of the energy of the incoming photon and is dependent on the atomic number of the material. The energy range in which pair production dominates is ≥ 25 MeV. This interaction occurs to some extent in routine radiation treatment with high-energy photon beams.

ELECTRON BEAMS

With the advent of high-energy linear accelerators, electrons have become a viable option in treating superficial tumors up to a depth of about 5 cm. Electron depth dose characteristics are unique in that they produce a high skin dose but exhibit a falloff after only a few centimeters.

Electron absorption in human tissue is greatly influenced by the presence of air cavities and bone. The dose is increased when the electron beam passes through an air space and is reduced when the beam passes through bone.

Common uses The most common clinical uses of electron beams include the treatment of skin lesions, such as basal cell carcinomas, and boosting of areas that have previously received photon irradiation, such as the postoperative lumpectomy or mastectomy scar in breast cancer patients, as well as select nodal areas in the head and neck.

MEASURING RADIATION ABSORPTION

The dose of radiation absorbed correlates directly with the energy of the beam. An accurate measurement of absorbed dose is critical in radiation treatment. The deposition of energy in tissues results in damage to DNA and diminishes or eradicates the cell’s ability to replicate indefinitely.

Gray The basic unit of radiation absorbed dose is the amount of energy (joules) absorbed per unit mass (kg). This unit, known as the gray (Gy), has replaced the unit of rad used in the past (100 rads = 1 Gy; 1 rad = 1 cGy).

Pages: 1  2  3  4  5  
Next
 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.





Table of Contents

14TH EDITION ONLINE ONLY

Cancer Management: A Multidisciplinary Approach

Medical, Surgical, & Radiation Oncology

 

Edited by
Daniel G. Haller, MD
Professor of Medicine Emeritus
Abramson Cancer Center at the University of Pennsylvania
 

Lawrence D. Wagman, MD
Executive Medical Director
The Center for Cancer Prevention and Treatment
St. Joseph Hospital
 

Kevin A. Camphausen, MD
Chief, Radiation Oncologist, National Cancer Institute

William J. Hoskins, MD
Executive Director of Surgical Activities
Memorial Sloan-Kettering Cancer Center
 

And the publishers of the journal ONCOLOGY

   

 


  

cancers of the head and neck region

Ch 1 Head and Neck Tumors
John Andrew Ridge, Bonnie S. Glisson, Miriam N. Lango, Steven Feigenberg

Ch 2 Thyroid and Parathyroid Cancers 
Erika Masuda Alford, Mimi I. Hu, Peter Ahn, Jeffrey P. Lamont

 

LUNG CANCER

Ch 3 Non-Small-Cell Lung Cancer
Benjamin Movsas, Julie Brahmer, Channing Paller, Kemp H. Kernstine

Ch 4 Small-Cell Lung Cancer, Mesothelioma, and Thymoma
Bonnie S. Glisson, Benjamin Movsas, Walter Scott, Robert A. Chapman

 

Breast cancer

Ch 5 Breast Cancer Overview Risk factors, screening, genetic testing, and prevention
Lori Jardines, Sharad Goyal, Paul Fisher, Jeffrey Weitzel, Melanie Royce, Shari B. Goldfarb

Ch 6 Stages 0 and I Breast Cancer
Lori Jardines, Sharad Goyal, Melanie Royce, Shari B. Goldfarb

Ch 7 Stage II Breast Cancer
Lori Jardines, Sharad Goyal, Melanie Royce, Shari B. Goldfarb

Ch 8 Stages III and IV Breast Cancer
Lori Jardines, Sharad Goyal, Melanie Royce, Ishmael Jaiyesimi, Shari B. Goldfarb

 

GASTROINTESTINAL CANCERS

Ch 9 Esophageal Cancer
Jimmy J. Hwang, Rajesh V. Iyer, Michael Mulligan

Ch 10 Gastric Cancer
Charles D. Blanke, Deborah Citrin, Roderich E. Schwarz

Ch 11 Pancreatic, Neuroendocrine GI, and Adrenal Cancers
Al B. Benson III, Robert J. Myerson, Aaron Sasson

Ch 12 Liver, Gallbladder, and Biliary Tract Cancers
Lawrence D. Wagman, John M. Robertson, Laura Raftery, Bert O'Neil, Keeran R. Sampat

Ch 13 Colon, Rectal, and Anal Cancers
Steven R. Alberts, Deborah Citrin, Miguel Rodriguez-Bigas

 

GENITOURINARY MALIGNANCIES

Ch 14 Prostate Cancer
Judd W. Moul, Andrew J. Armstrong, Joseph Lattanzi

Ch 15 Testicular Cancer
Patrick J. Loehrer, Atreya Dash, Mark K. Buyyounouski, Douglas Skarecky, Tareq Al Baghdadi

Ch 16 Urothelial and Kidney Cancers
Mark Hurwitz, Philippe E. Spiess, Jorge A. Garcia, Louis L. Pisters

 

GYNECOLOGIC MALIGNANCIES

Ch 17 Cervical Cancer
Leda Gattoc, Carlos A. Perez, William Tew, Sharmila Makhija

Ch 18 Uterine Corpus Tumors
Kathryn M. Greven, Maurie Markman, David Scott Miller

Ch 19 Ovarian Cancer
Stephen C. Rubin, Paul Sabbatini, Akila N. Viswanathan

 

SKIN CANCERS

Ch 20 Melanoma and Other Skin Cancers
Mary S. Brady, Aradhana Kaushal, Christine Ko, Keith Flaherty

 

Sarcomas

Ch 21 Bone Sarcomas
Warren Chow, Karl Haglund, R. Lor Randall

Ch 22 Soft-Tissue Sarcomas
Peter W. T. Pisters, Mitchell Weiss, Robert Maki

 

Brain TUMORS

Ch 23 Primary and Metastatic Brain Tumors
Jay S. Loeffler, John de Groot, Nicole Shonka, Daniel P. Cahill

 

other SOLID TUMORS

Ch 24 AIDS-Related Malignancies
Ronald T. Mitsuyasu, Deepa Reddy, Jay S. Cooper

Ch 25 Carcinoma of an Unknown Primary Site
John D. Hainsworth, Lawrence M. Weiss

 

hematologic malignancies

Ch 26 Hodgkin Lymphoma
Joachim Yahalom, David Straus, Dennis Eichenauer, Volker Diehl

Ch 27 Non-Hodgkin Lymphoma
Andrew M. Evens, Jane N. Winter, Leo I. Gordon, Brian C.-H. Chiu, Richard Tsang, Steven T. Rosen

Ch 28 Multiple Myeloma and Other Plasma Cell Dyscrasias
Sundar Jagannath, Paul Richardson, Nikhil C. Munshi

Ch 29 Acute Leukemias
Margaret R. O'Donnell

Ch 30 Chronic Myeloid Leukemia
Jorge E. Cortes, Richard T. Silver, Hagop Kantarjian

Ch 31 Chronic Lymphocytic Leukemia
Nicole Lamanna, Mark A. Weiss, Kieron Dunleavy

Ch 32 Myelodysplastic Syndromes
Guillermo Garcia-Manero, Alan List, Hagop Kantarjian, Jorge E. Cortes

Ch 33 Hematopoietic Cell Transplantation
Stephen J. Forman, Ryotaro Nakamura

 

Palliative and SUPPORTIVE CARE

Ch 34 Pain Management
Sharon M. Weinstein, Nora Janjan

Ch 35 Management of Nausea and Vomiting
Steven M. Grunberg, Nathan B. Adams, Richard Gralla

Ch 36 Fatigue and Dyspnea
Sriram Yennurajalingam, Eduardo Bruera

Ch 37 Anorexia and Cachexia
Aminah Jatoi

 

COMPLICATIONS

Ch 38 Oncologic Emergencies and Paraneoplastic Syndromes
Carmen P. Escalante, Ellen Manzullo, Mitchell Weiss

Ch 39 Infectious Complications
Sanjeet Dadwal, Jane Kriengkauykiat, James Ito

Ch 40 Fluid Complications
Frederic W. Grannis, Jr., Lily Lai

Ch 41 Long-Term Central Venous Access
Stephen P. Povoski
 

Color Atlases

Color Atlas 1: The ABCDEs of Moles and Melanomas

Color Atlas 2: Skin Lesions

Color Atlas 3: Dermatologic Toxicities Associated With Targeted Therapies
 

APPENDICES

Appendix 1: Response Evaluation Criteria and Performance Scales

Appendix 2: Cancer Information on the Internet
J. Sybil Biermann

Appendix 3: Cancer Drugs and Indications Newly Approved by the US Food and Drug Administration

Appendix 4: Chemotherapeutic Agents and Their Uses, Dosages, and Toxicities

Emiliano Calvo, MD, PhD and Antonio Calles, MD

 




CancerNetwork | CME LLC | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2012 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy